Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Horm Metab Res ; 44(12): 904-8, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22791600

ABSTRACT

Fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) is able to localize persistent or recurrent disease in differentiated thyroid carcinoma (DTC). The aim of the study was to correlate PET/CT results with precise intraoperative localization of persistent or recurrent papillary and follicular thyroid carcinoma. Patients with differentiated thyroid carcinoma who received FDG-PET scans were prospectively documented. The PET/CT results were correlated with other localization studies (neck ultrasound, ¹³¹I whole-body scan) and accurately compared to intraoperative findings and histopathological examinations. FDG-PET/CT scans were performed in 18 patients, between 16 and 84 years of age, from December 2008 to June 2011. Fourteen patients had papillary thyroid carcinomas and 4 had follicular thyroid carcinomas. All patients had a previous thyroidectomy and radioiodine ablation. Before cervical re-exploration, FDG-PET/CT-positive findings were reported in 14 individuals, whereas 4 PET scans provided no evidence of disease. Intraoperatively, 13 of 14 FDG-PET/CT-positive localizations of recurrent or persistent thyroid carcinomas were verified and confirmed by histopathology (sensitivity 93%). In another patient lymph node metastases of lung cancer were detected intraoperatively. However, FDG-PET/CT underestimated the number of lesions in 5 of 6 patients undergoing systematic lymphadenectomy. No lymph node or soft tissue metastases were found intraoperatively in 3 of the 4 patients with negative FDG-PET scans. A solitary cystic lymph node metastasis was found in the fourth patient but was not detected by FDG-PET/CT (specificity 75%). FDG-PET/CT has high sensitivity and specificity for the detection of persistent or recurrent differentiated thyroid carcinoma. FDG-PET/CT helps to select patients who might benefit from surgery because it provides precise anatomical details.


Subject(s)
Fluorodeoxyglucose F18/therapeutic use , Neoplasm Recurrence, Local/diagnostic imaging , Neoplasm Recurrence, Local/surgery , Radiopharmaceuticals/therapeutic use , Thyroid Neoplasms/diagnostic imaging , Thyroid Neoplasms/surgery , Adenocarcinoma, Follicular/diagnostic imaging , Adenocarcinoma, Follicular/pathology , Adenocarcinoma, Follicular/secondary , Adenocarcinoma, Follicular/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma/diagnostic imaging , Carcinoma/pathology , Carcinoma/secondary , Carcinoma/surgery , Carcinoma, Papillary , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Multimodal Imaging , Neoplasm Recurrence, Local/pathology , Neoplasm, Residual , Positron-Emission Tomography , Prospective Studies , Reoperation/adverse effects , Sensitivity and Specificity , Thyroid Cancer, Papillary , Thyroid Neoplasms/pathology , Tomography, X-Ray Computed , Young Adult
2.
Horm Metab Res ; 42(3): 209-14, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20013649

ABSTRACT

In patients with primary hyperparathyroidism (pHPT), positive preoperative localization studies enable to perform a minimally invasive approach for parathyroid surgery. However, current imaging techniques are not always successful. We therefore conducted a study to determine the sensitivity of C-11 methionine positron emission tomography/computed tomography (Met-PET/CT) in localizing parathyroid adenomas in pHPT. Met-PET/CT scans of the neck and mediastinum of 33 patients undergoing parathyroidectomy for primary HPT were compared with intraoperative and histological findings. Primary HPT was caused by a single gland adenoma in 30 patients, while another 3 patients had multiglandular disease. Met-PET/CT scan correctly located a single gland adenoma in 25 out of 30 (83%) patients with pHPT, among them 2 patients with persistent disease, 7 patients with prior neck surgery, and 8 patients with concomitant thyroid nodules. In 3 patients with multiglandular disease, Met-PET/CT showed only one enlarged parathyroid gland in two individuals and was negative in the third patient. Statistical analysis found a significant correlation between true-positive results and the weight (2.42+/-4.05 g) and diameter (2.0+/-1.18 cm) of parathyroid adenomas while the subgroup with false negative findings had significantly smaller (0.98+/-0.54 cm) and lighter (0.5+/-0.38 g) glands. Sensitivity was 83% for single gland adenomas and 67% for multiglandular disease. Met-PET/CT correctly localized 83% of single gland parathyroid adenomas in patients with pHPT. However, preoperative localization of multiglandular disease due to double adenomas or parathyroid hyperplasia remained difficult.


Subject(s)
Adenoma/diagnostic imaging , Hyperparathyroidism, Primary/diagnostic imaging , Methionine , Parathyroid Neoplasms/diagnostic imaging , Positron-Emission Tomography , Tomography, X-Ray Computed , Adenoma/complications , Adult , Aged , Aged, 80 and over , Female , Humans , Hyperparathyroidism, Primary/complications , Intraoperative Care , Male , Middle Aged , Neck/diagnostic imaging , Neck/surgery , Parathyroid Neoplasms/complications , Preoperative Care , Young Adult
3.
Phys Rev Lett ; 103(15): 152002, 2009 Oct 09.
Article in English | MEDLINE | ID: mdl-19905623

ABSTRACT

Azimuthal single-spin asymmetries of leptoproduced pions and charged kaons were measured on a transversely polarized hydrogen target. Evidence for a naive-T-odd, transverse-momentum-dependent parton distribution function is deduced from nonvanishing Sivers effects for pi(+), pi(0), and K(+/-), as well as in the difference of the pi(+) and pi(-) cross sections.

4.
Gut ; 57(6): 799-806, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18203806

ABSTRACT

BACKGROUND: Pancreatic ductal adenocarcinomas (PDACs) are highly resistant to treatment due to changes in various signalling pathways. CK1 isoforms play important regulatory roles in these pathways. AIMS: We analysed the expression levels of CK1 delta and epsilon (CK1delta/in) in pancreatic tumour cells in order to validate the effects of CK1 inhibition by 3-[2,4,6-(trimethoxyphenyl)methylidenyl]-indolin-2-one (IC261) on their proliferation and sensitivity to anti-CD95 and gemcitabine. METHODS: CK1delta/in expression levels were investigated by using western blotting and immunohistochemistry. Cell death was analysed by FACS analysis. Gene expression was assessed by real-time PCR and western blotting. The putative anti-tumoral effects of IC261 were tested in vivo in a subcutaneous mouse xenotransplantation model for pancreatic cancer. RESULTS: We found that CK1delta/in are highly expressed in pancreatic tumour cell lines and in higher graded PDACs. Inhibition of CK1delta/in by IC261 reduced pancreatic tumour cell growth in vitro and in vivo. Moreover, IC261 decreased the expression levels of several anti-apoptotic proteins and sensitised cells to CD95-mediated apoptosis. However, IC261 did not enhance gemcitabine-mediated cell death either in vitro or in vivo. CONCLUSIONS: Targeting CK1 isoforms by IC261 influences both pancreatic tumour cell growth and apoptosis sensitivity in vitro and the growth of induced tumours in vivo, thus providing a promising new strategy for the treatment of pancreatic tumours.


Subject(s)
Carcinoma, Pancreatic Ductal/pathology , Casein Kinase 1 epsilon/antagonists & inhibitors , Casein Kinase Idelta/antagonists & inhibitors , Indoles/pharmacology , Pancreatic Neoplasms/pathology , Phloroglucinol/analogs & derivatives , Animals , Antimetabolites, Antineoplastic/therapeutic use , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Carcinoma, Pancreatic Ductal/drug therapy , Carcinoma, Pancreatic Ductal/enzymology , Carcinoma, Pancreatic Ductal/secondary , Casein Kinase 1 epsilon/metabolism , Casein Kinase 1 epsilon/physiology , Casein Kinase Idelta/metabolism , Casein Kinase Idelta/physiology , Cell Proliferation/drug effects , Deoxycytidine/analogs & derivatives , Deoxycytidine/therapeutic use , Drug Evaluation, Preclinical , Humans , Indoles/therapeutic use , Lymphatic Metastasis , Mice , Mice, SCID , Neoplasm Transplantation , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/enzymology , Phloroglucinol/pharmacology , Phloroglucinol/therapeutic use , Transplantation, Heterologous , Tumor Cells, Cultured , fas Receptor/physiology , Gemcitabine
5.
Colorectal Dis ; 10(6): 612-5, 2008 Jul.
Article in English | MEDLINE | ID: mdl-17944970

ABSTRACT

OBJECTIVE: Anorectal melanoma is a rare, highly malignant tumour with a poor 5 year survival of 10%. Most anorectal melanomas have gross and/or histologic pigmentation, however about 30% of anorectal melanomas are amelanotic. METHOD: We report three cases of amelanotic anorectal melanomas and integrate our data with six case reports of amelanotic malignant melanoma from the literature. Further we compare clinicopathological data and clinical outcome with large series of anorectal melanomas (both, amelanotic and pigmentated). RESULTS: There were seven females and two males, of median age 62 years (range: 45-75 years). Rectal bleeding was the leading symptom in all cases with a mean duration of 4 months before diagnosis. Eight of nine patients developed distant metastases. Median survival was 14 months (range: 3-60 months). A tumour thickness of < 4 mm was correlated with long-term disease-free survival, whereas tumour thickness of 4 mm or more was correlated with systemic recurrence. CONCLUSION: Early diagnosis is key for efficient treatment and improved survival rate for patients with this unusual variant of melanoma. There is no difference in terms of age, time of diagnosis, stage and survival between pigmented and amelanotic anorectal melanoma.


Subject(s)
Anus Neoplasms , Melanoma, Amelanotic , Rectal Neoplasms , Aged , Anus Neoplasms/diagnosis , Anus Neoplasms/mortality , Anus Neoplasms/pathology , Female , Humans , Male , Melanoma, Amelanotic/diagnosis , Melanoma, Amelanotic/mortality , Melanoma, Amelanotic/pathology , Middle Aged , Rectal Neoplasms/diagnosis , Rectal Neoplasms/mortality , Rectal Neoplasms/pathology , Survival Rate
6.
Exp Clin Endocrinol Diabetes ; 113(10): 573-6, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16320154

ABSTRACT

Incipient diabetic retinopathy is characterized by increased capillary permeability and progressive capillary occlusion. The earliest structural change is the loss of pericytes (PC) from the retinal capillaries. With the availability of the XLacZ mouse, which expresses the LacZ reporter in a PC/vascular smooth muscle cell (vSMC) specific fashion, we quantitatively assessed the temporal dynamics of smooth muscle cells in arterioles under hyperglycemic conditions. We induced stable hyperglycemia in XLacZ mice. After 4, 8, and 12 weeks of diabetes retinae were isolated and beta-galactosidase/lectin stained. The numbers of smooth muscle cells were counted in retinal whole mounts, and diameters of retinal radial and branching arterioles and venules were analyzed at different distances apart from the center of the retina. After eight weeks of diabetes, the numbers of vSMCs were significantly reduced in radial arterioles 1000 microm distant from the optic disc. At proximal sites of branching arterioles (400 microm distant from the center), and at distal sites (1000 microm), vSMC were significantly reduced already after 4 weeks (to a maximum of 31 %). These changes were not associated with any measurable variation in vessel diameters. These data indicate quantitatively that hyperglycemia not only causes pericyte loss, but also loss of vSMCs in the retinal vasculature. Our data suggest that arteriolar vSMC in the eye underlie similar regulations which induce early pericyte loss in the diabetic retina.


Subject(s)
Arterioles/pathology , Diabetic Retinopathy/pathology , Muscle, Smooth, Vascular/pathology , Myocytes, Smooth Muscle/pathology , Animals , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/pathology , Diabetic Retinopathy/complications , Mice , Time Factors
7.
FASEB J ; 19(14): 2035-6, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16215210

ABSTRACT

Pericyte loss and capillary regression are characteristic for incipient diabetic retinopathy. Pericyte recruitment is involved in vessel maturation, and ligand-receptor systems contributing to pericyte recruitment are survival factors for endothelial cells in pericyte-free in vitro systems. We studied pericyte recruitment in relation to the susceptibility toward hyperoxia-induced vascular remodeling using the pericyte reporter X-LacZ mouse and the mouse model of retinopathy of prematurity (ROP). Pericytes were found in close proximity to vessels, both during formation of the superficial and the deep capillary layers. When exposure of mice to the ROP was delayed by 24 h, i.e., after the deep retinal layer had formed [at postnatal (p) day 8], preretinal neovascularizations were substantially diminished at p18. Mice with a delayed ROP exposure had 50% reduced avascular zones. Formation of the deep capillary layers at p8 was associated with a combined up-regulation of angiopoietin-1 and PDGF-B, while VEGF was almost unchanged during the transition from a susceptible to a resistant capillary network. Inhibition of Tie-2 function either by soluble Tie-2 or by a sulindac analog, an inhibitor of Tie-2 phosphorylation, resensitized retinal vessels to neovascularizations due to a reduction of the deep capillary network. Inhibition of Tie-2 function had no effect on pericyte recruitment. Our data indicate that the final maturation of the retinal vasculature and its resistance to regressive signals such as hyperoxia depend on the completion of the multilayer structure, in particular the deep capillary layers, and are independent of the coverage by pericytes.


Subject(s)
Capillaries/metabolism , Endothelium, Vascular/cytology , Retina/cytology , Angiopoietin-1/biosynthesis , Animals , Capillaries/cytology , Cell Survival , Densitometry , Diabetic Retinopathy/pathology , Genes, Reporter , Hypoxia , Immunoblotting , Lac Operon , Ligands , Mice , Neovascularization, Pathologic , Pericytes/cytology , Pericytes/metabolism , Phosphorylation , Platelet-Derived Growth Factor/metabolism , Receptor, TIE-2/metabolism , Retina/embryology , Retinal Vessels/pathology , Time Factors , Up-Regulation
8.
Eur J Surg Oncol ; 30(4): 407-13, 2004 May.
Article in English | MEDLINE | ID: mdl-15063894

ABSTRACT

AIMS: Thymidylate synthase (TS) is a key-enzyme for DNA synthesis and targeted by fluoropyrimidines (FPs). High TS ratios are associated with resistance to systemic FP-based chemotherapy. The aim of this study was to report the influence of TS ratios on primary tumour response to FP-based HAI and long-term follow-up of patients with isolated non-resectable liver tumours in part from a previously published study. METHODS: Fifty-one consecutive patients with liver tumours receiving HAI with available tumour tissue for TS quantitation were studied between 1991 and 2001. Liver metastases were from colorectal origin in 41 patients and other primary sites in 6 patients. Four patients had primary liver cancers. Tumour tissue was obtained at laparotomy for the intraarterial infusion device implantation. TS mRNA quantitation was performed by RT-PCR using beta-actin as internal standard. RESULTS: The median TS ratio was 2.2 with high variation among tumours ranging from 0.1 to 27. Twenty-two out of 51 patients responded to HAI. The median TS ratio of the responders was 1.6 and more than two-fold lower than the ratio of the non-responders with 3.3 (p < 0.01). In the subgroup with TS3.0 only four out of 22 patients responded. No patients with very high TS ratios >or=4.5 ( n = 13) responded to HAI. Median survival was 20 months (range: 3-109). Patients with TS-ratios 3.0 with 27%. CONCLUSION: TS seems to be a predictive and prognostic factor for patients with isolated non-resectable liver tumours receiving FP-based HAI. Patients with very high TS ratios do not seem to benefit from FP-based HAI.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colorectal Neoplasms/drug therapy , Liver Neoplasms/drug therapy , Thymidylate Synthase/metabolism , Adult , Aged , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Epirubicin/administration & dosage , Female , Fluorouracil/administration & dosage , Follow-Up Studies , Humans , Infusions, Intra-Arterial , Liver Neoplasms/metabolism , Liver Neoplasms/secondary , Male , Middle Aged , Prognosis , Survival Analysis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...